Use of nicotine, pharmaceutical compositions and pharmaceutical combination product

摘要

Use of a nicotine or a pharmaceutically acceptable salt or derivative thereof together with a pharmaceutically acceptable carrier in the preparation of a medicament for delivering said nicotine to the rectum, colon and/or terminal ileum of a patient for the treatment, or prophylaxis or remission of inflammatory bowel disease. A rectally administrable pharmaceutical composition or post-gastric delayed release oral pharmaceutical composition comprising nicotine or a salt or a pharmaceutically acceptable derivative thereof together with a pharmaceutically acceptable carrier. A post-gastric delayed release oral composition which is in the form of an enterically coated capsule or a capsule containing enterically coated microgranules or an enterically coated capsule containing enterically coated microgranules. A pharmaceutical combination product comprising nicotine or salt or a pharmaceutically acceptable derivative thereof adapted for delivery to the terminal ileum or colon, and a compound selected from 5-ASA, sulphasalazine, asalazine, prednisolone or budesonide for simultaneous separate or sequential administration.